A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 17.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Fintel reports that on November 24, 2025, Barclays maintained coverage of Incyte (NasdaqGS:INCY) with a Overweight recommendation. Analyst Price Forecast Suggests 7.38% Downside As of November 17, ...

Incyte’s Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 ...

Jefferies analyst Kelly Shi maintained a Buy rating on Incyte today and set a price target of $120.00. Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest ...

Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura ...

Warning: This article contains spoilers for Spider-Man: No Way Home! The mid-credits scene for Spider-Man: No Way Home features none other than Venom, picking up where we left him in the post-credits ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with ...

Thinking about whether Incyte might be worth more than its current price tag? You are not alone, as many investors are asking the same question right now. The stock has surged 46.8% year-to-date, ...

Spider veins and varicose veins are two types of damaged blood vessels. They occur when blood becomes backed up in eroding valves. A spider vein is essentially a milder form of a varicose vein.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and ...